AstraZeneca

AZN · NYSE · USD

$156.90−0.51%−$0.80

Close · October 2, 2026

At a glance

Revenue growth
+8.63%
2025 vs 2024
Net income growth
+45.34%
2025 vs 2024
Net margin
17.4%
2024: 13.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets115,833114,015114,074114,456112,422106,253104,035104,922104,340102,293101,11996,086
Current assets27,96529,61328,72329,94028,93926,13925,82724,15525,39325,59425,05422,501
Cash and equivalents4,8937,5605,7118,1437,0585,2305,4884,7976,9167,8415,8404,871
Short-term investments75.01158.039.050.0165—133160180—244
Receivables15,98915,16514,30115,15315,16914,81513,09413,54712,62212,22511,93511,997
Inventory6,9326,5706,5576,5936,4675,8845,2885,6625,6675,3375,4245,292
Net property, plant and equipment16,30014,94114,70313,78313,22912,30311,64711,51310,83310,61610,5029,700
Goodwill21,18121,19421,24221,21921,22221,13021,02521,13921,06019,97820,04819,939
Other intangible assets37,72336,90837,84638,19137,92537,55037,17739,39439,42638,83438,08937,687
Long-term investments2,9162,6652,5252,2862,1391,9001,9002,1451,8711,6951,6771,290
Current liabilities31,55332,57030,61734,05433,53629,12927,86625,92628,56628,90130,54228,588
Accounts payable22,89322,5053,82025,02823,98622,5443,64021,68420,46319,6993,26719,723
Long-term debt23,68624,46224,71524,70024,71426,74126,62128,92127,28627,31022,40322,300
Total debt29,40131,02029,05930,94830,90830,32430,13030,37230,59633,237——
Total liabilities65,46366,63165,35568,48567,61265,12263,16464,11764,74264,79261,95358,865
Total equity (incl. minority)50,37047,38448,71945,97144,81041,13140,87140,80539,59837,50139,16637,221
Retained earnings12,5929,67212,5998,2137,0233,3647,2293,1381,847-2124,516-434
Minority interest75.051.052.083.091.092.085.086.086.056.023.024.0